http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-100237-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10e4b1416c6e66e0ade5429212414964 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704 |
| filingDate | 2015-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f16b6582a60f5ddec44b936c36dfa23 |
| publicationDate | 2016-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-100237-A1 |
| titleOfInvention | LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH MULTIPLE RECURRENT MULTIPLE SCLEROSIS (RRMS) WITH A HIGH DEGREE OF DISABILITY |
| abstract | A method of treating or reducing ambulatory impairment in a human patient with a diagnosis of recurrent remitting multiple sclerosis (RRMS) and who has a high baseline disability score according to the Kurtzke Expanded Status of Disability Scale (EDSS), which comprises periodically administering only to the patient with a diagnosis of RRMS and who has a high baseline disability score, an amount of effective laquinimod to treat the patient or to reduce ambulatory impairment. It also provides pharmaceutical compositions and packages that comprise an effective amount of laquinimod to treat a human patient with a diagnosis of RRMS and that has a high baseline disability score according to the EDSS. |
| priorityDate | 2014-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54677946 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419530079 |
Total number of triples: 13.